TOP TEN perturbations for NM_000032 (Homo sapiens)

Organism: Homo sapiens
Gene: NM_000032
Selected probe(set): 211560_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of NM_000032 (211560_s_at) across 5339 perturbations tested by GENEVESTIGATOR:

systemic onset JIA study 4 / juvenile enthesitis related arthritis study 2 (ERA)

Relative Expression (log2-ratio):7.4241924
Number of Samples:3 / 3
Experimental systemic onset JIA study 4
Peripheral blood mononuclear cell (PBMC) samples from children with systemic onset of juvenile rheumatoid arthritis (JIA).
Control juvenile enthesitis related arthritis study 2 (ERA)
Peripheral blood mononuclear cell (PBMC) samples from children with enthesitis related arthritis (ERA).

systemic onset JIA study 4 / oligoarticular JIA study 3

Relative Expression (log2-ratio):6.4629736
Number of Samples:3 / 12
Experimental systemic onset JIA study 4
Peripheral blood mononuclear cell (PBMC) samples from children with systemic onset of juvenile rheumatoid arthritis (JIA).
Control oligoarticular JIA study 3
Peripheral blood mononuclear cell (PBMC) samples from children with persistent oligoarthritis (oligoarticular JIA).

systemic onset JIA study 5 / polyarticular JIA study 4 (RF negative)

Relative Expression (log2-ratio):6.2958374
Number of Samples:3 / 17
Experimental systemic onset JIA study 5
Peripheral blood mononuclear cell (PBMC) samples from children with recent onset and systemic onset of juvenile rheumatoid arthritis (SoJIA). All patients were free of disease modifying antirheumatic drugs or biologics. Subjects were classified according to ILAR criteria. Patients were enrolled in the study very early in the disease course, hence difference between disease onset and age at sampling is small (<4-8 month).
Control polyarticular JIA study 4 (RF negative)
Peripheral blood mononuclear cell (PBMC) samples from children with recent onset of polyarticular juvenile idiopathic arthritis, rheumatoid factor negative (polyJIA, RF neg.). All patients were free of disease modifying antirheumatic drugs or biologics. Subjects were classified according to ILAR criteria. Patients were enrolled in the study very early in the disease course, hence difference between disease onset and age at sampling is small (<4-8 month).

systemic onset JIA study 5 / oligoarticular JIA study 2

Relative Expression (log2-ratio):6.260005
Number of Samples:3 / 12
Experimental systemic onset JIA study 5
Peripheral blood mononuclear cell (PBMC) samples from children with recent onset and systemic onset of juvenile rheumatoid arthritis (SoJIA). All patients were free of disease modifying antirheumatic drugs or biologics. Subjects were classified according to ILAR criteria. Patients were enrolled in the study very early in the disease course, hence difference between disease onset and age at sampling is small (<4-8 month).
Control oligoarticular JIA study 2
Peripheral blood mononuclear cell (PBMC) samples from children with recent onset of persistent oligoarticular juvenile idiopathic arthritis (JIA). All patients were free of disease modifying antirheumatic drugs or biologics. Subjects were classified according to ILAR criteria. Patients were enrolled in the study very early in the disease course, hence difference between disease onset and age at sampling is small (<4-8 month).

systemic onset JIA study 4 / polyarticular JIA study 6

Relative Expression (log2-ratio):6.197014
Number of Samples:3 / 14
Experimental systemic onset JIA study 4
Peripheral blood mononuclear cell (PBMC) samples from children with systemic onset of juvenile rheumatoid arthritis (JIA).
Control polyarticular JIA study 6
Peripheral blood mononuclear cell (PBMC) samples from children with rheumatoid factor negative polyarthritis (RF- polyarthritis/RF- polyarticular JIA).

systemic onset JIA study 4 / normal PBMC sample

Relative Expression (log2-ratio):5.782978
Number of Samples:3 / 27
Experimental systemic onset JIA study 4
Peripheral blood mononuclear cell (PBMC) samples from children with systemic onset of juvenile rheumatoid arthritis (JIA).
Control normal PBMC sample
Peripheral blood mononuclear cell (PBMC) samples from healthy children.

systemic onset JIA study 5 / normal PBMC sample

Relative Expression (log2-ratio):5.7350044
Number of Samples:3 / 27
Experimental systemic onset JIA study 5
Peripheral blood mononuclear cell (PBMC) samples from children with recent onset and systemic onset of juvenile rheumatoid arthritis (SoJIA). All patients were free of disease modifying antirheumatic drugs or biologics. Subjects were classified according to ILAR criteria. Patients were enrolled in the study very early in the disease course, hence difference between disease onset and age at sampling is small (<4-8 month).
Control normal PBMC sample
Peripheral blood mononuclear cell (PBMC) samples from healthy children.

juvenile enthesitis related arthritis study 1 (ERA) / systemic onset JIA study 3

Relative Expression (log2-ratio):-5.0012274
Number of Samples:26 / 18
Experimental juvenile enthesitis related arthritis study 1 (ERA)
Peripheral blood mononuclear cell (PBMC) samples from children with enthesitis related arthritis (ERA). All patients were free of disease modifying antirheumatic drugs.
Control systemic onset JIA study 3
Peripheral blood mononuclear cell (PBMC) samples from children with systemic onset of juvenile rheumatoid arthritis (JIA). All patients were free of disease modifying antirheumatic drugs.

B-CLL study 5 / normal bone marrow sample

Relative Expression (log2-ratio):-4.92848
Number of Samples:441 / 74
Experimental B-CLL study 5
Bone marrow samples of patients with B-cell chronic lymphocytic leukemia (B-CLL).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

systemic onset JIA study 3 / polyarticular JIA study 3 (RF positive)

Relative Expression (log2-ratio):4.7821646
Number of Samples:18 / 15
Experimental systemic onset JIA study 3
Peripheral blood mononuclear cell (PBMC) samples from children with systemic onset of juvenile rheumatoid arthritis (JIA). All patients were free of disease modifying antirheumatic drugs.
Control polyarticular JIA study 3 (RF positive)
Peripheral blood mononuclear cell (PBMC) samples from children with rheumatoid factor negative (RFpos) polyarticular juvenile rheumatoid arthritis. All patients were free of disease modifying antirheumatic drugs.